# US 2021/0329895 A1 · Non-human animals having a humanized b-cell activating factor gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0329895 A1
- Document ID: US20210329895A1
- Status: Published application
- Kind: A1
- Application number: 17/226,125
- Filed: 2021-04-09
- Published: 2021-10-28
- Earliest claimed: 2013-11-19
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: John McWhirter; Cagan Gurer; Lynn Macdonald; Andrew J. Murphy
- Web page: https://patentgrep.com/patent/US20210329895A1

## CPC

- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C12N 15/85: for animal cells
- G01N 33/5088: {of vertebrates}
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2207/15: Humanized animals
- A01K 2217/07: Animals genetically altered by homologous recombination
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A01K 2267/0325: Animal model for autoimmune diseases
- A01K 2267/0381: Animal model for diseases of the hematopoietic system
- A01K 2267/0387: Animal model for diseases of the immune system
- C07K 2319/00: Fusion polypeptide
- G01N 2500/10: involving cells
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described.

## Claims

### Claim at position 1

-21. (canceled)

### Claim 22

An isolated mouse cell or tissue whose genome comprises
a replacement of a mouse genomic fragment comprising exons 3-6 of an endogenous mouse B-cell Activating Factor (Baff) gene at an endogenous mouse Baff locus in the mouse ES cell, with a human genomic fragment comprising exons 3-6 of a human BAFF gene to form a humanized Baff gene,
wherein the coding exons of the humanized Baff gene consist of exons 1-2 of the endogenous mouse Baff gene and exons 3-6 of the human BAFF gene,
wherein the humanized Baff gene is under control of the mouse Baff promoter at the endogenous mouse Baff locus and encodes a humanized Baff protein comprising an extracellular portion of the human BAFF protein linked to an intracellular portion of the mouse Baff protein encoded by the endogenous mouse Baff gene,
wherein the extracellular portion of the human BAFF protein is at least 98% identical to the amino acid sequence as set forth in amino acids 142 to 285 of SEQ ID NO: 5, and
wherein the mouse cell or tissue expresses thed humanized Baff protein.

### Claim 23 (depends on 22)

The mouse cell or tissue of claim 22, wherein the extracellular portion of the human BAFF protein consists of amino acids 142 to 285 of SEQ ID NO: 5.

### Claim 24 (depends on 22)

The mouse cell or tissue of claim 22, wherein the humanized Baff protein consists of the amino acid sequence as set forth in SEQ ID NO: 7.

### Claim 25

A cell or tissue isolated from a mouse, wherein the mouse genome comprises
a replacement of a mouse genomic fragment comprising exons 3-6 of an endogenous mouse B-cell Activating Factor (Baff) gene at an endogenous mouse Baff locus in the mouse ES cell, with a human genomic fragment comprising exons 3-6 of a human BAFF gene to form a humanized Baff gene,
wherein the coding exons of the humanized Baff gene consist of exons 1-2 of the endogenous mouse Baff gene and exons 3-6 of the human BAFF gene,
wherein the humanized Baff gene is under control of the mouse Baff promoter at the endogenous mouse Baff locus and encodes a humanized Baff protein comprising an extracellular portion of the human BAFF protein linked to an intracellular portion of the mouse Baff protein encoded by the endogenous mouse Baff gene,
wherein the extracellular portion of the human BAFF protein is at least 98% identical to the amino acid sequence as set forth in amino acids 142 to 285 of SEQ ID NO: 5,
wherein the mouse expresses the humanized Baff protein, and
wherein the cell or tissue comprises the humanized Baff gene.

### Claim 26 (depends on 25)

The mouse cell or tissue of claim 25, wherein the extracellular portion of the human BAFF protein consists of amino acids 142 to 285 of SEQ ID NO: 5.

### Claim 27 (depends on 25)

The mouse cell or tissue of claim 25, wherein the humanized Baff protein consists of the amino acid sequence as set forth in SEQ ID NO: 7.

### Claim 28

A targeting vector, comprising
a human genomic fragment comprising exons 3-6 of a human BAFF gene, flanked by a 5′ nucleic acid sequence and a 3′ nucleic acid sequence,
wherein the 5′ nucleic acid sequence comprises (i) about 14.5 kb mouse genomic sequence upstream of exon 1 of a mouse Baff gene, and (ii) exon 1 and exon 2 of the mouse Baff gene,
wherein the 3′ nucleic acid sequence comprises a mouse genomic sequence 3′ to the mouse Baff gene,
wherein the 5′ and 3′ nucleic acid sequences mediate integration of the human genomic fragment into a mouse Baff locus which results in a replacement of a genomic fragment of the mouse Baff gene to form a humanized Baff gene,
wherein the coding exons of the humanized Baff gene consist of exons 1-2 of the mouse Baff gene and exons 3-6 of the human BAFF gene,
wherein the humanized Baff gene is under control of the mouse Baff promoter at the mouse Baff locus and encodes a humanized Baff protein comprising an extracellular portion of the human BAFF protein linked to an intracellular portion of the mouse Baff protein encoded by the mouse Baff gene, and
wherein the extracellular portion of the human BAFF protein is at least 98% identical to the amino acid sequence as set forth in amino acids 142 to 285 of SEQ ID NO: 5.

### Claim 29 (depends on 28)

The targeting vector of claim 28, wherein the extracellular portion of the human BAFF protein consists of amino acids 142 to 285 of SEQ ID NO: 5.

### Claim 30 (depends on 28)

The targeting vector of claim 28, wherein the humanized Baff protein consists of the amino acid sequence as set forth in SEQ ID NO: 7.
